Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161583 · ClinicalTrials.gov registry record
Advanta VXT and Flixene PMCF Registry
A clinical trial of Peripheral Arterial Disease, sponsored by Atrium Medical Corporation.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 2
- Study locations
NCT07161583: Recruiting study of Peripheral Arterial Disease, sponsored by Atrium Medical Corporation.
NCT07161583 is a study of Peripheral Arterial Disease that is actively recruiting participants, run by Atrium Medical Corporation. The registered enrollment target is 1,000 participants, below the 4,194-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07161583, a study of Peripheral Arterial Disease, is actively recruiting participants, sponsored by Atrium Medical Corporation.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular grafts.
Primary Outcome
Primary patency defined as freedom from graft occlusion or reintervention
Conditions Studied
Interventions
- DEVICE Advanta VXT Vascular Graft
- DEVICE Flixene Vascular Graft
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Brittany Region
- CHU de Brest - Brest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2026-10 |
What NCT07161583 shows while recruiting
NCT07161583 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 4,194-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Advanta VXT Vascular Graft is the first listed.
NCT07161583 reports a single indexed study location in Massachusetts, Brittany Region.
Frequently Asked Questions
What is clinical trial NCT07161583 about?
NCT07161583 is a clinical study titled "Advanta VXT and Flixene PMCF Registry". The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular graft...
What is the current status of trial NCT07161583?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-09-25. Estimated completion is 2026-10.
What conditions does trial NCT07161583 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT07161583?
The interventions under investigation include: Advanta VXT Vascular Graft (DEVICE), Flixene Vascular Graft (DEVICE).
Who is sponsoring clinical trial NCT07161583?
This trial is sponsored by Atrium Medical Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161583 being conducted?
This trial has 2 study locations across Massachusetts, Brittany Region. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07161583's enrollment target sits among peer trials
1,000 5th of 79 higher than 75 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI